MBX Biosciences (MBX) TD Cowen 46th Annual Health Care Conference summary

Key program updates and clinical milestones

• Achieved strong phase II results in hypoparathyroidism and advanced an obesity candidate, MBX 4291, into the clinic in 2025.

• Planning to initiate a global phase III study for canvorparotide in Q3 2026, with phase II one-year follow-up data expected in Q2.

• Anticipating 12-week multiple ascending dose data for MBX 4291 in Q4, targeting improved tolerability and once-monthly dosing.

• Expanding the obesity portfolio with new candidates targeting amylin and glucagon, with development candidates to be declared in Q2 and Q3.

• Strong financial position with cash runway into 2029, supporting all planned clinical and pre-commercial activities.

Technology platform and differentiation

• Precision Endocrine Peptides (PEP) platform enables slow, steady drug release for improved tolerability and less frequent dosing.

• Platform incorporates programmable prodrug technology and fatty acylation to extend drug action and reduce dosing frequency.

• Technology is clinically validated and designed by a leading peptide chemist, supporting best-in-class product candidates.

• Differentiated PK profile aims to provide both monthly dosing and better tolerability, especially in obesity treatments.

Clinical data highlights and expectations

• Canvorparotide phase II showed significant response rates in hypoparathyroidism, with 79% responder rate at six months and high patient retention.

• One-year open-label extension data will include bone mineral density and safety, with expectations for maintained response rates.

• Phase III study design will align with established endpoints and sample sizes from comparable trials, with a focus on convenience and efficacy.

• MBX 4291 phase I/II studies in obesity will assess PK, tolerability, and weight loss, with a stepwise approach to dose selection and titration.